Ataxia-Telangiectasia: Comprehensive Disease Characterization Report

Summary

Ataxia-telangiectasia (A-T) is an autosomal recessive, multisystem disorder caused by biallelic loss-of-function mutations in the ATM gene (chromosome 11q22.3), which encodes a 3,056-amino-acid serine/threonine protein kinase of the phosphatidylinositol 3-kinase-related kinase (PIKK) family. ATM is the master regulator of the cellular DNA double-strand break (DSB) response, and its absence disrupts DNA repair, cell cycle checkpoints, apoptosis, redox homeostasis, and mitochondrial function. The disease presents as a phenotypic continuum from severe classical childhood-onset A-T—characterized by progressive cerebellar ataxia, oculocutaneous telangiectasia, combined immunodeficiency, a 56-fold increased cancer risk, and progressive pulmonary disease—to milder adult-onset variant forms, with disease severity determined by residual ATM kinase activity.

Epidemiologically, A-T affects approximately 1 in 40,000 to 1 in 100,000 live births worldwide, with autosomal recessive inheritance and a carrier frequency of approximately 1–3% in the general population. The Kaplan-Meier 20-year survival rate is 53.4%, with cancer and respiratory tract infections independently associated with mortality. Patients with null ATM mutations experience earlier cancer onset (primarily hematologic malignancies), while those with hypomorphic mutations more often succumb to respiratory infections. There is no curative therapy, but multidisciplinary supportive care—including immunoglobulin replacement, aggressive pulmonary management, and cancer surveillance—improves quality of life. Emerging therapies including triheptanoin (targeting mitochondrial dysfunction) and intra-erythrocyte dexamethasone (sustained corticosteroid delivery) have shown promise in clinical trials.

The pathophysiology involves interconnected mechanisms of defective DSB repair, oxidative stress targeting cerebellar Purkinje cells, mitochondrial dysfunction with impaired ER-mitochondrial connectivity, neuroinflammation via the cGAS-STING pathway driven by cytosolic DNA accumulation, and impaired V(D)J/class-switch recombination leading to immunodeficiency. This report provides a comprehensive characterization across 15 disease dimensions with ontology annotations and evidence citations to support knowledge base population.

1. Disease Information

Overview

Ataxia-telangiectasia (A-T), also known as Louis-Bar syndrome, is a rare autosomal recessive neurodegenerative disorder first described in 1926 and later characterized by Madame Louis-Bar in 1941. It is classified as both a primary immunodeficiency and a genomic instability syndrome. A-T is characterized by progressive cerebellar ataxia typically manifesting in early childhood, oculocutaneous telangiectasia, variable immunodeficiency, radiosensitivity, susceptibility to malignancies, and metabolic abnormalities including insulin resistance and endocrine dysfunction. As summarized in a comprehensive review: "Ataxia-telangiectasia (A-T) is an autosomal recessive primary immunodeficiency (PID) disease that is caused by mutations in ataxia-telangiectasia mutated (ATM) gene encoding a serine/threonine protein kinase. A-T patients represent a broad range of clinical manifestations including progressive cerebellar ataxia, oculocutaneous telangiectasia, variable immunodeficiency, radiosensitivity, susceptibility to malignancies, and increased metabolic diseases" (PMID: 30685876).

Key Identifiers

Synonyms and Alternative Names

• Ataxia-telangiectasia (A-T)
• Louis-Bar syndrome
• Boder-Sedgwick syndrome
• ATM syndrome / ATM deficiency
• Cerebello-oculocutaneous telangiectasia

Data Sources

This report is derived from aggregated disease-level resources including OMIM, Orphanet, GeneReviews, ClinVar, published cohort studies (particularly European A-T registries from France, Netherlands, Germany, and the UK), clinical trials, and primary research literature comprising 78 reviewed papers.

2. Etiology

Disease Causal Factors

A-T is a monogenic Mendelian disorder caused exclusively by biallelic pathogenic variants in the ATM gene (OMIM *607585), located on chromosome 11q22.3. ATM encodes a 3,056-amino-acid serine/threonine protein kinase belonging to the phosphatidylinositol 3-kinase-related kinase (PIKK) family. The ATM protein is the master regulator of the cellular DNA damage response (DDR), specifically activated by DNA double-strand breaks (DSBs). "ATM is a central kinase that activates an extensive network of responses to cellular stress via a signaling role. ATM is activated by DNA double strand breaks (DSBs) and by oxidative stress, subsequently phosphorylating a plethora of target proteins" (PMID: 34573351). The disease is genetic in origin with no environmental or infectious causative factors (PMID: 9735376).

Genetic Risk Factors

• Causal variants: Over 600 distinct pathogenic variants reported in ATM, including truncating (nonsense, frameshift), splice-site, missense, and large genomic rearrangements (e.g., a 90-kb duplication spanning exons 17–61; PMID: 30888062)
• Genotype-phenotype correlation: The definitive genotype-phenotype study of 51 patients established that "patients without ATM kinase activity showed the classical phenotype. The presence of ATM protein, correlated with slightly better immunological function. Residual kinase activity correlated with a milder and essentially different neurological phenotype, absence of telangiectasia, normal endocrine and pulmonary function, normal immunoglobulins, significantly lower X-ray hypersensitivity in lymphocytes, and extended lifespan" (PMID: 22213089)
• Founder mutations: Population-specific founder mutations identified in North Caucasus ethnic groups (PMID: 37851290), Kyrgyzstan (homozygous c.5932G>A; PMID: 41451872), Ashkenazi Jewish, and other populations
• Consanguinity: Significantly increases risk; "the findings confirm that consanguineous unions increase the risk of developing Louis-Bar syndrome, as they elevate the likelihood of inheriting identical mutant alleles" (PMID: 41451872)
• Modifier genes: The DNA damage checkpoint gene HUS1 modifies A-T severity; simultaneous ATM and HUS1 defects cause synthetic lethality in mice (PMID: 22575700)

Heterozygous Carrier Risk

ATM heterozygous carriers (~1–3% of the general population) have a moderately increased cancer risk. "ATM germline pathogenic variants (GPVs) are associated with a moderately increased risk of female breast cancer, pancreatic cancer, and prostate cancer" (PMID: 39636577). The pooled prevalence of ATM variants in breast cancer patients was 7% (95% CI: 5–8%) (PMID: 34493284).

Environmental Risk Factors

• Ionizing radiation: A-T patients are exquisitely radiosensitive; exposure to therapeutic radiation can cause severe, potentially fatal toxicity. Diagnostic imaging with ionizing radiation should be avoided when possible; radiation-free techniques (US, MRI) are recommended (PMID: 36186632)
• Genotoxic chemicals: Radiomimetic agents and topoisomerase inhibitors pose increased risk due to defective DSB repair

Protective Factors

• Residual ATM kinase activity: The single most important modifier; even small amounts of residual kinase activity significantly ameliorate disease course (PMID: 22213089)
• Antioxidants: The antioxidant CTMIO was shown to correct neurobehavioral deficits and reduce oxidative damage to Purkinje cells in Atm−/− mice, dramatically delaying thymic lymphoma onset (PMID: 16934683)
• NAD+ supplementation: Boosting intracellular NAD+ alleviates senescence phenotypes and mitochondrial dysfunction in ATM-deficient cells (PMID: 33734555)

Gene-Environment Interactions

ATM heterozygotes carrying rare missense variants of uncertain significance showed increased risk of radiation-associated contralateral breast cancer (carriers with RT: RR = 2.98, 95% CI 1.31–6.80 vs. without RT: RR = 0.38, 95% CI 0.09–1.55), suggesting gene-radiation interaction (PMID: 32119081). In homozygous A-T patients, elevated Cu/Zn-SOD paradoxically exacerbated radiosensitivity and hematopoietic abnormalities, consistent with oxidative stress contributing to the phenotype (PMID: 11285218).

3. Phenotypes

Neurological Phenotypes

Dermatological Phenotypes

Immunological Phenotypes

Detailed immunological analysis confirmed that "patients with AT have a broad spectrum of cellular and humoral deficiencies" (PMID: 33052516), and "immunoglobulin deficiency in AT is caused by disturbed development of class-switched memory B cells. ATM deficiency affects both germinal center reaction and choice of DNA-repair pathway in class switching" (PMID: 38280573).

Pulmonary Phenotypes

FVC declines from 67 ± 8% predicted while walking to 19 ± 6% predicted at end-stage. A sharp elevation in FEF25-75/FVC ratio was observed when FEV1 was ~45% predicted, approximately 2 years prior to death (PMID: 26033643). Lung disease in A-T "shows similarities to the lung disease seen in cystic fibrosis" (PMID: 23761391).

Oncological Phenotypes

Cancer risk is 56-fold increased overall (SIR = 56, 95% CI: 33–88) in a population-based German cohort: "Among the 160 patients with AT, we observed 19 cases of childhood cancer (15 cases of lymphoma, three cases of leukemia, and one case of medulloblastoma) versus 0.32 expected" (PMID: 34597127). Non-Hodgkin lymphoma SIR = 470 (95% CI: 225–865); Hodgkin lymphoma SIR = 215 (95% CI: 58–549). Approximately 14% of patients develop cancer by age 18.

Endocrine and Metabolic Phenotypes

Mean weight, height, and BMI Z-scores were −1.0, −1.2, and −0.4 respectively, with 35/101 children having weight Z-scores below −2. Decline was most obvious after age 8 (PMID: 27573920).

Laboratory Abnormalities

Quality of Life Impact

A-T profoundly impacts quality of life across multiple domains: progressive loss of ambulation (typically by age 10–12), speech deterioration, swallowing difficulty, increasing dependence for all activities of daily living, chronic respiratory symptoms, frequent infections, fatigue, and social isolation. Cancer treatment is further complicated by radiosensitivity.

4. Genetic/Molecular Information

Causal Gene

• Gene: ATM (Ataxia-Telangiectasia Mutated)
• HGNC ID: HGNC:795
• NCBI Gene ID: 472
• OMIM: *607585
• Chromosomal location: 11q22.3
• Gene structure: 66 exons spanning ~150 kb of genomic DNA
• Protein: 3,056 amino acids, ~370 kDa

ATM belongs to the PIKK family, sharing structural features including N-terminal HEAT repeats, FAT domain, kinase domain, and C-terminal FATC domain. "A characteristic PIKK member comprises of an N-terminal HEAT domain, followed by FAT domain, a highly conserved kinase catalytic domain, and a C-terminal FATC domain" (PMID: 32114444). "The FATC domain of ATM mediates the interaction between ATM and Tip60, a histone acetyltransferase that regulates activation of ATM" (PMID: 16603769). The three-dimensional structure reveals that "the highly conserved C-terminal PIKK catalytic domain forms a central structure from which FAT and FATC domains protrude" (PMID: 15698568).

Pathogenic Variants

• Variant types: Truncating (~85% in classical A-T: nonsense, frameshift), splice-site (~15%), missense (~10% overall), large deletions/duplications
• Classification: >800 variants in ClinVar; majority classified as pathogenic or likely pathogenic
• Novel variants: Continuously identified, including a 90-kb duplication spanning exons 17–61 detected by NGS (PMID: 30888062) and compound heterozygous mutations in diverse populations (PMID: 37009283; PMID: 41044616)
• Functional consequence: Predominantly loss-of-function; null mutations abolish kinase activity (classical A-T); hypomorphic mutations retain residual activity (variant A-T)
• Somatic vs. germline: A-T is caused by germline biallelic mutations. Somatic ATM mutations are frequent in various cancers; approximately 3% of lung cancers harbor biallelic ATM mutations (PMID: 38807759)
• Population frequency: Carrier frequency ~1–3% (1 in 50–100). Individually rare variants but collectively common

Modifier Genes

• HUS1: Modifies A-T severity; simultaneous ATM and HUS1 defects cause synthetic lethality, while partial Hus1 impairment with Atm loss produces synergistic increases in genomic instability and developmental defects (PMID: 22575700)
• SOD1: Elevated Cu/Zn-SOD exacerbates the A-T phenotype, suggesting redox balance is a modifier (PMID: 11285218)

Epigenetic Information

ATM deficiency leads to impaired DNA damage-induced histone modifications, particularly γH2AX phosphorylation. ATM regulates chromatin remodeling through its interaction with the Tip60 histone acetyltransferase and through phosphorylation of KAP1/TRIM28. ATM phosphorylates SPOP at Ser119, promoting non-degradative ubiquitination of HIPK2, which then phosphorylates HP1γ to promote dissociation from H3K9me3 marks for DNA damage repair (PMID: 34133717). ATM-mediated senescence involves STING-dependent pathways and SASP (PMID: 33734555).

Chromosomal Abnormalities

Characteristic cytogenetic findings include inversions and translocations involving chromosomes 7 and 14 at TCR and immunoglobulin gene loci: inv(7)(p14q35), t(7;14)(p14;q11.2), t(14;14)(q11.2;q32). "At the cellular level, one of the most prominent features of A-T cells is chromosome rearrangement, especially that in T lymphocytes" (PMID: 34440406).

5. Environmental Information

Environmental Factors

• Ionizing radiation: The most critical environmental factor. A-T patients are extremely radiosensitive; diagnostic imaging should use non-ionizing methods (US, MRI) whenever possible (PMID: 36186632)
• Genotoxic chemicals: Radiomimetic agents and topoisomerase inhibitors pose increased risk

Lifestyle Factors

• Nutrition: Growth failure is progressive; PEG tube feeding should be considered proactively from age 8 (PMID: 27573920)
• Physical activity: Adapted exercise encouraged for respiratory and general health; limited by progressive ataxia
• Respiratory care: Avoidance of respiratory irritants is critical given pulmonary vulnerability

Infectious Agents

A-T patients are susceptible to common bacterial respiratory pathogens due to immunodeficiency. In younger patients (<15 years), Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pneumoniae predominate (25/27 cultured positive), while in older patients, Pseudomonas aeruginosa becomes prevalent (35/47 cultured positive). "Opportunistic infections of the lungs were not observed" (PMID: 23761391). Chronic EBV infection has been associated with more severe outcomes in hyper-IgM A-T patients (PMID: 36340711).

6. Mechanism / Pathophysiology

Molecular Pathways

ATM is the central kinase of the DSB response. Upon DSB induction, the MRN complex (MRE11-RAD50-NBS1) recognizes breaks and recruits ATM, which undergoes autophosphorylation and monomerization. Active ATM phosphorylates >1,000 downstream substrates including H2AX (γH2AX), CHK2 (Thr68), p53 (Ser15), SMC1 (Ser966), KAP1/TRIM28 (Ser824), BRCA1, and NBS1.

Key disrupted pathways: DNA damage response (GO:0006974), p53 signaling (KEGG: hsa04115), homologous recombination (KEGG: hsa03440), non-homologous end joining (KEGG: hsa03450), V(D)J recombination (GO:0033151), and cell cycle checkpoint control (GO:0000077).

Cellular Processes and Causal Chains

DNA Repair Deficiency (Upstream)

ATM-deficient neurons exhibit "defective repair of DNA double-strand breaks (DSBs) and repressed phosphorylation of ATM substrates (e.g., γH2AX, Smc1-S966, Kap1-S824, Chk2-T68, p53-S15), but normal repair of single-strand breaks" and "abnormal accumulation of topoisomerase 1-DNA covalent complexes (Top1-ccs)" (PMID: 25032865).

Oxidative Stress (Parallel/Amplifying)

"Organs which develop pathologic changes in the Atm-deficient mice are targets of oxidative damage, and cerebellar Purkinje cells are particularly affected" (PMID: 10449794). Chronic oxidative stress involves endogenous ROS overproduction, NADPH oxidase 4 (NOX4) activation, and impaired antioxidant defense (PMID: 28063379).

Mitochondrial Dysfunction (Intermediate)

"A-T cells demonstrate defective endoplasmic reticulum-mitochondrial connectivity disrupting calcium homoeostasis and mitochondrial fusion, which are corrected in vitro by the triheptanoin metabolite, heptanoate" (PMID: 40616902). Senescence phenotypes and SASP in ATM-deficient cells are mediated through STING and involve ectopic cytoplasmic DNA (PMID: 33734555).

Neuroinflammation via cGAS-STING (Downstream)

"Loss of Atm in neurons and glia leads to accumulation of cytosolic DNA, increased cytokine production and constitutive activation of microglia consistent with a neuroinflammatory phenotype. Rats lacking ATM had significant loss of motor neurons and microgliosis in the spinal cord, consistent with onset of paralysis" (PMID: 28007901).

Impaired Class-Switch Recombination (Downstream)

"Immunoglobulin deficiency in AT is caused by disturbed development of class-switched memory B cells. ATM deficiency affects both germinal center reaction and choice of DNA-repair pathway in class switching" (PMID: 38280573).

Pathophysiology Model

ATM Gene Mutation (Biallelic Loss-of-Function)
 │
 ▼
    Loss of ATM Kinase Activity
 │
    ┌────┼────────────────────┬──────────────────────────┐
    ▼    ▼                    ▼                          ▼
Defective   Impaired Redox   Impaired V(D)J    Defective Cell
DSB Repair  Regulation        & CSR             Cycle Checkpoints
    │         │                  │                    │
    ▼         ▼                  ▼                    ▼
Genomic     Oxidative         Immunodeficiency   Radiosensitivity
Instability Stress            ↓IgA, IgG, Hyper-IgM
    │         │                  │
    ▼         ▼                  ▼
Cancer     Mitochondrial     Recurrent Infections
Predisposition Dysfunction    Pulmonary Disease
    │         │                  │
    │         ▼                  ▼
    │    Cytosolic DNA       Respiratory Failure
    │    Accumulation
    │         │
    │         ▼
    │    cGAS-STING Activation
    │    Neuroinflammation
    │         │
    │         ▼
    │    Progressive Cerebellar
    │    Neurodegeneration
    └─────────┘
 │
 ▼
   Multisystem Disease

Cell Types Involved

GO Terms for Key Processes

• GO:0006302 — Double-strand break repair
• GO:0006974 — Cellular response to DNA damage stimulus
• GO:0000723 — Telomere maintenance
• GO:0007050 — Cell cycle arrest
• GO:0006915 — Apoptotic process
• GO:0006955 — Immune response
• GO:0033151 — V(D)J recombination
• GO:0045087 — Innate immune response (cGAS-STING)
• GO:0006979 — Response to oxidative stress
• GO:0000077 — DNA damage checkpoint signaling

Metabolic Changes

A-T patients exhibit insulin resistance and glucose intolerance. Mitochondrial dysfunction leads to altered energy metabolism. Chronic DNA damage activates PARP, depleting NAD+ stores (PMID: 33734555). Triheptanoin provides heptanoate to bypass ER-mitochondrial connectivity disruption through anaplerosis (PMID: 40616902).

Biochemical Abnormalities

• Elevated serum AFP (>95% of patients; mechanism not fully understood)
• Absent or reduced ATM protein (Western blot) and kinase activity
• Deficient γH2AX foci formation after radiation
• Radioresistant DNA synthesis (absent intra-S phase checkpoint)
• Elevated liver transaminases (40–60%)

7. Anatomical Structures Affected

Organ Level

Subcellular Level

Localization

Neurological and vascular manifestations are bilateral and symmetric: cerebellar atrophy (UBERON:0002129), conjunctival telangiectasia (UBERON:0001811), and bronchial disease (UBERON:0001555) all affect both sides.

8. Temporal Development

Onset

• Typical age: 1–4 years for gait ataxia (insidious onset)
• Variant A-T: Later onset (adolescence to adulthood); dystonia may be initial symptom (PMID: 37009283)

Progression

• Progression rate: Relentlessly progressive for neurological features; respiratory decline accelerates in adolescence
• Disease course: Progressive, chronic, lifelong; no remissions
• Historical median survival: ~19–25 years for classical A-T

Critical Periods

• Age 8 years: Growth decline accelerates; proactive nutritional intervention recommended (PMID: 27573920)
• Adolescence: Cancer risk peaks; pulmonary function rapidly declines
• FVC ~45% predicted: Sharp elevation in FEF25-75/FVC ratio signals imminent respiratory decompensation, approximately 2 years prior to death (PMID: 26033643)

9. Inheritance and Population

Epidemiology

Inheritance

• Pattern: Autosomal recessive (AR)
• Penetrance: Complete for biallelic null mutations; variable for hypomorphic alleles
• Expressivity: Variable; correlates with residual ATM kinase activity
• Genetic anticipation: Not observed (not a repeat expansion disorder)
• Consanguinity: Important factor, particularly in Central Asian and Middle Eastern communities (PMID: 41451872)

Founder Effects

Population-specific founder mutations documented in: - North Caucasus ethnic groups (BRCA1/ATM; PMID: 37851290) - Kyrgyz population (c.5932G>A; PMID: 41451872) - Ashkenazi Jewish, Amish/Mennonite, Japanese, and other populations

Population Demographics

• Sex ratio: Approximately 1:1 (autosomal recessive, no sex predilection)
• Ethnic distribution: All ethnicities affected; higher in consanguineous populations
• Geographic distribution: Worldwide; registries in Europe, North America, and other regions

10. Diagnostics

Clinical Tests

Genetic Testing

The recommended approach is: 1. Clinical suspicion based on progressive ataxia + elevated AFP ± immunodeficiency 2. ATM gene sequencing (Sanger or NGS) as confirmatory test 3. MLPA or array CGH for large deletions/duplications 4. WES/WGS for atypical presentations

"Next-generation sequencing (NGS) revealed two novel heterozygous mutations in the ATM gene... demonstrating the utility of targeted NGS in the detection of copy number variation" (PMID: 30888062).

Differential Diagnosis

Screening

• Newborn screening: Not standard; TREC-based SCID screening may incidentally identify severe cases
• Carrier screening: ATM included in expanded carrier screening panels
• Prenatal testing: Available for families with known mutations (CVS, amniocentesis)
• PGD: Available for carrier couples

11. Outcome/Prognosis

Survival and Mortality

The French cohort of 240 A-T patients demonstrated: "the Kaplan-Meier 20-year survival rate was 53.4%; the prognosis for these patients has not changed since 1954. Life expectancy was lower among patients with mutations in ATM that caused total loss of expression or function of the gene product (null mutations) compared with that seen in patients with hypomorphic mutations because of earlier onset of cancer (mainly hematologic malignancies). Cancer (hazard ratio, 2.7; 95% CI, 1.6-4.5) and respiratory tract infections (hazard ratio, 2.3; 95% CI, 1.4-3.8) were independently associated with mortality" (PMID: 21665257).

The Dutch cohort confirmed: "classical AT patients had a shorter survival than variant patients (HR 5.9, 95%CI 2.0-17.7), especially once a malignancy was diagnosed (HR 2.5, 95%CI 1.1-5.5, compared to classical AT patients without malignancy)" (PMID: 28126470).

Genotype-Stratified Mortality

Prognostic Factors

12. Treatment

Pharmacotherapy

There is currently no curative pharmacotherapy for A-T. Treatment is primarily supportive and multidisciplinary.

Advanced Therapeutics

Triheptanoin (Phase 2a/b trial, 31 participants): An anaplerotic medium-chain triglyceride targeting mitochondrial dysfunction. Results showed significant improvements at maximum dose vs. placebo (PMID: 40616902): - Nasal cell death: MD = −9.7% (95% CI −16.0, −4.6) - SARA kinetic function: MD = −5.8 (95% CI −10.4, −1.2) - ICARS gait: MD = −0.5 (95% CI −0.9, −0.1) - Speech intelligibility: MD = −12.8 (95% CI −21.2, −4.3) - Swallowing safety: MD = −0.9 (95% CI −1.6, −0.3)

Intra-erythrocyte dexamethasone (ATTeST Phase 3 trial): "Corticosteroids can improve neurological functioning in patients with the disorder but adrenal suppression and symptom recurrence on treatment discontinuation has limited their use, prompting the development of novel steroid delivery systems." Multicentre, randomised, double-blind, placebo-controlled at 22 centres in 12 countries (PMID: 39152028).

Antioxidant therapy: CTMIO "dramatically delays the onset of thymic lymphomas in Atm(−/−) mice" and "corrects neurobehavioral deficits in these mice and reduces oxidative damage to Purkinje cells" (PMID: 16934683).

NAD+ supplementation: Ameliorates senescence and mitochondrial dysfunction in ATM-deficient cells through STING pathway modulation (PMID: 33734555).

Cell therapy: Adipose-derived MSCs explored for pulmonary tissue regeneration (PMID: 32531978).

Supportive and Rehabilitative Care

Cancer Treatment Considerations

• Radiation therapy: Must be avoided or drastically reduced; standard doses can be fatal
• Chemotherapy: Modified protocols; radiomimetic agents require dose modification
• PARP inhibitors: Show synthetic lethality with ATM loss in cancer cells, relevant for somatic ATM-mutant tumors (PMID: 38807759)

13. Prevention

Primary Prevention

• Genetic counseling (MAXO:0000079): Essential for families with affected children and consanguineous populations
• Carrier screening: ATM included in expanded carrier screening panels
• Prenatal diagnosis: CVS or amniocentesis available when familial mutations known
• Preimplantation genetic diagnosis (PGD): Available for carrier couples

Secondary Prevention

• Elevated AFP + ataxia → immediate ATM genetic testing; "early ATM genetic testing should be considered for those patients with predominant dystonia, despite without accompanying ataxia or telangiectasia" (PMID: 37009283)
• TREC-based newborn screening: May incidentally identify severe cases
• Cancer surveillance: Regular clinical assessment; avoid ionizing radiation; use US/MRI (PMID: 39264246)

Tertiary Prevention

ATM Heterozygote Cancer Screening

"ATM GPV heterozygotes should generally be offered enhanced breast surveillance according to their personalized risk estimate and country-specific guidelines and, generally, risk-reducing mastectomy is not recommended. Prostate cancer surveillance should be considered. Pancreatic cancer surveillance should be considered based on assessment of family history" (PMID: 39636577).

14. Other Species / Natural Disease

Orthologous Genes

Comparative Biology

ATM function is evolutionarily ancient and conserved from yeast to humans. In S. cerevisiae, "the Tel1 kinase (ortholog of human ATM) is activated at DNA double-strand breaks (DSBs) and short telomeres" and controls "telomere maintenance, suppression of chromosomal rearrangements, activation of cell cycle checkpoints, and repair of DSBs" (PMID: 39826692). Novel phosphoproteomic analysis revealed a D/E-S/T motif unique to Tel1 signaling, providing insights into specialized ATM functions.

A-T has not been widely documented as a naturally occurring disease in companion animals. The disease is not zoonotic.

15. Model Organisms

Mouse Models (Atm−/−)

• Types: Conventional knockouts (multiple alleles), conditional knockouts
• Phenotype recapitulation:
• ✅ Thymic lymphomas (100% penetrance by ~4–6 months)
• ✅ Immunodeficiency (T/B cell defects, CSR impairment)
• ✅ Radiosensitivity, growth retardation, infertility, chromosomal instability
• ❌ Does NOT recapitulate progressive cerebellar degeneration (major limitation)
• ⚠️ Subtle neurobehavioral deficits and oxidative damage to Purkinje cells detectable (PMID: 10449794)
• Antioxidant studies: CTMIO "dramatically delays the onset of thymic lymphomas" and "corrects neurobehavioral deficits" (PMID: 16934683)
• Modifier studies: Hus1 impairment + Atm loss → synthetic lethality or synergistic genomic instability (PMID: 22575700); SOD1 overexpression exacerbates phenotype (PMID: 11285218)

Rat Models

• Superior neurological model: "Loss of Atm in neurons and glia leads to accumulation of cytosolic DNA, increased cytokine production and constitutive activation of microglia consistent with a neuroinflammatory phenotype. Rats lacking ATM had significant loss of motor neurons and microgliosis in the spinal cord, consistent with onset of paralysis" (PMID: 28007901)
• ✅ Neuroinflammation, motor neuron loss, cytosolic DNA accumulation, paralysis

Cellular Models

• iPSC-derived neurons: Recapitulate DSB repair defects, repressed ATM substrate phosphorylation, Top1-cc accumulation (PMID: 25032865)
• Brain-derived and iPSC-derived neural stem cells: Model neurodegeneration (PMID: 23598976)
• Patient fibroblasts: Show mitochondrial dysfunction, senescence, SASP (PMID: 33734555)

Yeast (S. cerevisiae)

• TEL1 ortholog: Telomere maintenance, DSB signaling; novel D/E-S/T motif identified (PMID: 39826692)

Model Limitations

Key Findings — Detailed Evidence

Finding 1: Biallelic ATM Mutations Cause A-T with Genotype-Phenotype Correlation

The ATM gene on chromosome 11q22.3 encodes a 3,056-amino-acid serine/threonine kinase that is the master regulator of the DNA double-strand break response. Biallelic loss-of-function mutations cause autosomal recessive A-T. A landmark genotype-phenotype study of 51 patients demonstrated that patients without ATM kinase activity display classical A-T, while "residual kinase activity correlated with a milder and essentially different neurological phenotype, absence of telangiectasia, normal endocrine and pulmonary function, normal immunoglobulins, significantly lower X-ray hypersensitivity in lymphocytes, and extended lifespan" (PMID: 22213089). This genotype-phenotype correlation—centered on residual ATM kinase activity—is the single most important prognostic factor and has transformed our understanding of A-T as a disease continuum rather than a single entity. Prevalence is estimated at 1:40,000–1:100,000 live births, with a cancer risk 56-fold increased (SIR = 56; PMID: 34597127).

Finding 2: Cerebellar Neurodegeneration Driven by DNA Damage and cGAS-STING Neuroinflammation

The most debilitating feature of A-T—progressive cerebellar degeneration—results from a cascade beginning with defective DSB repair and culminating in neuroinflammation. ATM-deficient neurons show "defective repair of DNA double-strand breaks (DSBs) and repressed phosphorylation of ATM substrates" and "abnormal accumulation of topoisomerase 1-DNA covalent complexes" (PMID: 25032865). Cerebellar Purkinje cells are selectively vulnerable to oxidative damage (PMID: 10449794). Unrepaired DNA leads to cytosolic DNA accumulation that activates the cGAS-STING innate immune pathway: "Loss of Atm in neurons and glia leads to accumulation of cytosolic DNA, increased cytokine production and constitutive activation of microglia" (PMID: 28007901). The nitroxide antioxidant CTMIO "corrects neurobehavioral deficits in these mice and reduces oxidative damage to Purkinje cells" (PMID: 16934683), confirming oxidative stress as a tractable therapeutic target.

Finding 3: Survival Determined by Cancer and Respiratory Infections with Genotype Stratification

In the French cohort of 240 A-T patients, "the Kaplan-Meier 20-year survival rate was 53.4%; the prognosis for these patients has not changed since 1954." Cancer (HR 2.7, 95% CI 1.6–4.5) and respiratory tract infections (HR 2.3, 95% CI 1.4–3.8) were independently associated with mortality. For null mutations, cancer is the major risk factor (HR 5.8, 95% CI 2.9–11.6); for hypomorphic mutations, respiratory infections lead (HR 4.1, 95% CI 1.8–9.1) (PMID: 21665257). The Dutch cohort confirmed that "classical AT patients had a shorter survival than variant patients (HR 5.9, 95% CI 2.0–17.7)" (PMID: 28126470).

Finding 4: Immunodeficiency from Defective Class-Switch Recombination

The immunodeficiency in A-T reflects fundamental defects in lymphocyte development and function. "Immunoglobulin deficiency in AT is caused by disturbed development of class-switched memory B cells. ATM deficiency affects both germinal center reaction and choice of DNA-repair pathway in class switching" (PMID: 38280573). Comprehensive analysis revealed "a broad spectrum of cellular and humoral deficiencies" (PMID: 33052516). The hyper-IgM phenotype is particularly significant as a poor prognostic marker, associated with chronic EBV expansion and liver failure (PMID: 36340711).

Finding 5: Triheptanoin and Intra-Erythrocyte Dexamethasone Show Clinical Promise

Two therapeutic approaches have advanced to clinical trials. Triheptanoin showed significant improvements in a Phase 2a/b trial across multiple endpoints (nasal cell death MD = −9.7%, SARA kinetic MD = −5.8, speech intelligibility MD = −12.8), targeting mitochondrial dysfunction as "A-T cells demonstrate defective endoplasmic reticulum-mitochondrial connectivity disrupting calcium homoeostasis and mitochondrial fusion, which are corrected in vitro by the triheptanoin metabolite, heptanoate" (PMID: 40616902). The ATTeST Phase 3 trial of intra-erythrocyte dexamethasone leverages corticosteroid neurological benefits while minimizing systemic effects through encapsulated delivery (PMID: 39152028).

Evidence Base

Landmark Papers

Evidence Types

The evidence base comprises 78 papers spanning: - Human clinical data: Cohort studies from France (n=240; PMID: 21665257), Netherlands (PMID: 28126470), Germany (n=160; PMID: 34597127), and multinational clinical trials - Model organism data: Mouse (PMID: 10449794; PMID: 16934683), rat (PMID: 28007901), yeast (PMID: 39826692) - In vitro data: iPSC-derived neurons (PMID: 25032865), patient fibroblasts (PMID: 33734555) - Clinical trials: Triheptanoin Phase 2a/b (PMID: 40616902), ATTeST Phase 3 (PMID: 39152028)

Ontology Term Summary

HPO Terms (Phenotype)

HP:0001251 (Cerebellar ataxia), HP:0000657 (Oculomotor apraxia), HP:0000989 (Telangiectasia), HP:0000565 (Conjunctival telangiectasia), HP:0002721 (Immunodeficiency), HP:0002664 (Neoplasm), HP:0006254 (Elevated AFP), HP:0200144 (Radiosensitivity), HP:0003220 (Chromosomal instability), HP:0001260 (Dysarthria), HP:0001332 (Dystonia), HP:0001266 (Choreoathetosis), HP:0009830 (Peripheral neuropathy), HP:0001888 (Lymphopenia), HP:0004313 (↓IgA), HP:0004315 (↓IgG), HP:0002790 (Hyper-IgM), HP:0002205 (Recurrent respiratory infections), HP:0002110 (Bronchiectasis), HP:0001510 (Growth delay), HP:0000855 (Insulin resistance), HP:0000135 (Hypogonadism), HP:0007495 (Premature aging)

GO Terms (Biological Process)

GO:0006302 (DSB repair), GO:0006974 (DNA damage response), GO:0000077 (DNA damage checkpoint), GO:0006915 (Apoptosis), GO:0033151 (V(D)J recombination), GO:0045087 (Innate immune response), GO:0006979 (Oxidative stress response), GO:0000723 (Telomere maintenance)

GO Terms (Cellular Component)

GO:0005634 (Nucleus), GO:0005739 (Mitochondrion), GO:0005783 (ER), GO:0005737 (Cytoplasm), GO:0000785 (Chromatin)

CL Terms (Cell Types)

CL:0000121 (Purkinje cell), CL:0000084 (T cell), CL:0000236 (B cell), CL:0000129 (Microglia), CL:0000100 (Motor neuron), CL:0000788 (Naive B cell), CL:0000972 (Class-switched memory B cell), CL:0002368 (Respiratory epithelial cell), CL:0000115 (Endothelial cell)

UBERON Terms (Anatomy)

UBERON:0002037 (Cerebellum), UBERON:0002370 (Thymus), UBERON:0002048 (Lung), UBERON:0001811 (Conjunctiva), UBERON:0002107 (Liver), UBERON:0002240 (Spinal cord), UBERON:0002371 (Bone marrow), UBERON:0000991 (Gonad)

MAXO Terms (Treatment)

MAXO:0001298 (Immunoglobulin replacement), MAXO:0000747 (Antimicrobial therapy), MAXO:0000079 (Genetic counseling), MAXO:0001001 (Gastrostomy), MAXO:0000487 (Physical therapy), MAXO:0000536 (Occupational therapy), MAXO:0000930 (Speech therapy)

MONDO Term

MONDO:0008840 (Ataxia-telangiectasia)

Limitations and Knowledge Gaps

1. Neurodegeneration mechanism: The precise reason why cerebellar Purkinje cells are selectively vulnerable to ATM loss remains incompletely understood. The relative contributions of DSB repair failure, oxidative stress, mitochondrial dysfunction, and neuroinflammation are still debated (PMID: 32871349).

2. Mouse model limitations: Atm knockout mice do not develop progressive cerebellar ataxia or Purkinje cell loss, making preclinical neurological studies challenging. The rat model is superior but still shows spinal cord rather than cerebellar pathology (PMID: 28007901; PMID: 23598976).

3. Stagnant prognosis: Despite decades of study, "the prognosis for these patients has not changed since 1954" (PMID: 21665257), highlighting the urgent need for disease-modifying therapies.

4. Limited trial data: Clinical trials are constrained by small sample sizes inherent to rare diseases (triheptanoin trial: n=31). Long-term efficacy data are lacking for all emerging therapies.

5. Variant A-T underdiagnosis: Atypical presentations (dystonia-predominant, adult-onset) are likely underdiagnosed; the full phenotypic spectrum of hypomorphic ATM mutations is not yet defined (PMID: 37009283).

6. Heterozygote cancer risk: Precise penetrance estimates for different ATM variant types and cancer types remain uncertain (PMID: 39636577).

7. Multi-omic characterization: Comprehensive epigenomic, proteomic, and metabolomic profiling of A-T tissues—particularly at single-cell resolution—is still limited.

8. Pulmonary pathogenesis: The etiology of progressive pulmonary deterioration beyond immunodeficiency is unclear; direct ATM roles in respiratory epithelium require investigation (PMID: 17524020).

Proposed Follow-up Experiments/Actions

1. Single-cell transcriptomics of A-T cerebellum: Profile Purkinje cells, granule cells, and microglia from A-T patient post-mortem tissue to define cell-type-specific transcriptional changes and validate the cGAS-STING neuroinflammation axis in human tissue.

2. STING inhibitor trials: Given demonstrated cGAS-STING involvement in neuroinflammation (PMID: 28007901), evaluate STING pathway inhibitors in the ATM-deficient rat model.

3. NAD+ supplementation clinical trial: Translate preclinical findings that NAD+ boosting ameliorates senescence and mitochondrial dysfunction (PMID: 33734555) into a clinical trial.

4. Long-term triheptanoin follow-up: Extend the Phase 2a/b trial to assess disease progression rate modification and survival benefit.

5. Global genotype-phenotype registry: Establish a registry linking detailed ATM genotype (including residual kinase activity) with longitudinal clinical outcomes.

6. Biomarker development: Develop non-invasive biomarkers (neurofilament light chain, cytokine panels, circulating cytosolic DNA) for disease monitoring and clinical trial design.

7. Gene therapy approaches: Investigate dual-AAV, lentiviral, or base editing strategies for ATM restoration in neural progenitors and HSCs.

8. ATM heterozygote prospective cohort: Establish prospective surveillance to refine cancer penetrance estimates.

Report generated: 2026-05-05 Data sources: OMIM, Orphanet, ClinVar, PubMed, and 78 reviewed publications Evidence quality: High for genetic/molecular mechanisms; moderate for clinical outcomes; emerging for therapeutic interventions